Skip to main content

Table 2 Clinical characteristics at baseline for all patients and at 6, 12, 18 and 24 months for 30% responders to erenumab

From: Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

 

Baseline

Month 6

Month 12

Month 18

Month 24

(n = 160)

(n = 76)

(n = 61)

(n = 52)

(n = 36)

MD

19.8 ± 9.0

6.9 ± 5.2*

9.1 ± 7.7*

8.7 ± 8.7*

8.8 ± 8.0*

HD

23.4 ± 7.3

11.0 ± 8.2*

12.0 ± 8.5*

12.0 ± 9.6*

11.3 ± 8.7*

Headache free days

3.8 ± 5.7

7.8 ± 8.2**

11.5 ± 10.1**

11.6 ± 10.3**

13.3 ± 10.3**

Abortive treatment intake days

11.6 ± 8.8

5.6 ± 5.9*

7.4 ± 7.8**

6.4 ± 6.8**

6.2 ± 5.1**

HIT-6

67.6 ± 4.9

56.7 ± 7.7**

57.5 ± 9.0**

58.0 ± 9.6**

54.5 ± 8.2**

  1. All values are expressed in mean monthly numbers
  2. HD Headache days, MD Migraine days, MMD Monthly migraine days
  3. *P < 0.001, **P < 0.05